Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones

Core Viewpoint - Biofrontera Inc. has successfully locked the databases for two clinical studies evaluating Ameluz PDT, marking a significant milestone ahead of expected data and regulatory events in 2026 [1][2][10] Group 1: Clinical Studies and Data - The databases for the Phase 3 clinical study on Ameluz PDT for actinic keratosis (AK) and the Phase 2 study for moderate to severe acne vulgaris were locked on January 5, 2026 [2][10] - Data from these studies will be available in February 2026, enabling statistical analysis and unblinding of results [3][10] - Actinic keratosis and acne vulgaris are the most commonly diagnosed skin disorders in the US, affecting tens of millions of patients [3][10] Group 2: Market Opportunity and Unmet Needs - There is a significant unmet need for effective treatments for AK and acne vulgaris, with current therapies often limited by side effects [4][12] - The U.S. acne treatment market was valued at $5.7 billion in 2024 and is projected to grow at a 5.3% CAGR, highlighting the demand for safer alternatives [12] - The potential for increased use of Ameluz PDT is noted, especially if approved for broader indications beyond the face and scalp [4][5] Group 3: Regulatory Plans - Pending positive outcomes from the Phase 3 AK study, the company plans to submit a supplemental New Drug Application (sNDA) to the FDA in Summer 2026 [5][6] - Results from the Phase 2 acne vulgaris study are expected to be presented to the FDA in early Q3 2026, which will support a future Phase 3 program [5][6] Group 4: Company Overview - Biofrontera Inc. specializes in the treatment of dermatological conditions using photodynamic therapy (PDT) and commercializes Ameluz for treating AK and other skin lesions [13]